TYR and neoplasm: Preclinical evidence utilising ATN-161 loaded reversibly cross-linked polymersomes for drug delivery into C57BL/6 mice bearing B16-F10 tumours demonstrated significant inhibition of tumour growth, and significantly improved survival rates (Zhang et al., 2017).